Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of AC0010 in Patients With Relapsed or Refractory CLL/SLL, MCL, DLBCL and Other Non-Hodgkin B-Cell Lymphoma

NCT03060850 is registered in ClinicalTrials.gov with Hangzhou ACEA Pharmaceutical Research Co., Ltd. as lead sponsor.

NCT NCT03060850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03060850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of AC0010 in Patients With Relapsed or Refractory CLL/SLL, MCL, DLBCL and Other Non-Hodgkin B-Cell Lymphoma
Lead sponsor
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
March 17, 2017
Completion date
December 14, 2020
Enrollment
184 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma